ArticleBMC cancer2020

Cost-effectiveness analysis comparing companion diagnostic tests for EGFR, ALK, and ROS1 versus next-generation sequencing (NGS) in advanced adenocarcinoma lung cancer patients.

Luciene Schluckebier et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.